[시장보고서]지질 나노입자 시장 규모, 점유율, 동향 분석 보고서 : LNP별, 분자별, 용도별, 적응증별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

지질 나노입자 시장 규모, 점유율, 동향 분석 보고서 : LNP별, 분자별, 용도별, 적응증별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Lipid Nanoparticle Market Size, Share & Trends Analysis Report By LNP (Liposomes, Nanostructured Lipid Carriers), By Molecule (mRNA, siRNA), By Application, By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1726195

리서치사 : Grand View Research, Inc.

발행일 : 2025년 04월

페이지 정보 : 영문 120 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

지질 나노입자 시장 성장과 동향

Grand View Research, Inc.의 새로운 보고서에 따르면 세계의 지질 나노입자 시장은 2030년까지 15억 4,000만 달러에 이를 것으로 예상되며, 예측 기간 동안 13.64%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

지질 시장은 특히 유전자 치료, 종양학, 백신 등의 부문에서 첨단 약물 전달 시스템에 대한 수요가 증가함에 따라 큰 성장을 이루고 있습니다. 직접 캡슐화 및 전달을 위한 매우 효율적인 방법을 기재하고 있습니다. 공공기관과 민간기업 모두에 의한 연구개발활동의 급증과 나노메디신에 대한 투자의 확대는 제약 및 생명공학 부문 전체에서 LNP 기반의 약제제제의 광범위한 채용을 지원하는데 중요한 역할을 하고 있습니다.

mRNA 백신의 LNP 기반 전달 시스템을 이용한 COVID-19 백신의 개발은 유행중에 큰 주목과 자원을 모았습니다. COVID-19 치료와 백신의 심사·승인 프로세스를 가속화했습니다. 이로써 COVID-19 치료의 신속한 시장 진입이 촉진되었지만, 다른 치료 영역에서 LNP 기반 제품의 규제 경로와 기준을 합리화할 필요성이 부각되어 향후 규제 프레임워크과 시장의 역학을 형성할 가능성

게다가 전략적 제휴, 지질 제제의 기술적 진보, 정밀의료에 대한 의식 증가가 계속해서 시장의 성장을 뒷받침하고 있습니다. 하이브리드 시스템, 표면 개질 등의 혁신은 희귀 유전성 질환을 포함한 복잡한 질환의 치료에 있어서의 LNP의 범위를 확대하고 있습니다.

지질 나노입자 시장 보고서의 하이라이트

LNP별로는 리포솜 부문이 2024년 최대의 수익 점유율로 시장 전체를 지배했습니다.
분자별로는 mRNA부문이 2024년에 최대의 수익 점유율로 시장 전체를 지배했고 예측기간 중에 가장 빠른 CAGR을 나타낼 것으로 예측됩니다.
2024년에는 치료가 용도부문에서 우위를 차지했습니다.
2024년에는 암이 적응증 부문을 지배했고 예측기간 중에 높은 CAGR을 나타낼 것으로 예상되고 있습니다.
제약 및 생명공학 기업이 최종 용도 부문을 지배하고, 학술·연구 기관 부문이 예측 기간 중에 가장 빠른 CAGR을 나타낼 전망입니다.
감염증의 부담이 큰 것, 구매력평가가 높은 것, 질 높은 의료에 대한 정부의 지원이 있는 것, 상환이 가능한 것 등의 요인에 의해 2024년 시장은 북미가 지배적이었습니다.

시장 세분화 및 범위
시장 계통의 전망
- 모 시장 전망
- 관련/보조시장 전망
시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
산업 분석도구
- SWOT 분석, 요인별(정치·법률, 경제 기술)
- Porter's Five Forces 분석
- COVID-19의 영향 분석

제4장 지질 나노입자 시장 : LNP 비즈니스 분석

부문 대시보드
지질 나노입자의 전체적인 변동 분석
세계의 지질 나노입자 시장 규모와 동향 분석 - LNP별(2018-2030년)
리포솜
고체 지질 나노입자
나노 구조 지질 캐리어
기타

제5장 지질 나노입자 시장 : 분자 비즈니스 분석

부문 대시보드
지질 나노입자의 전체적인 변동 분석
세계의 지질 나노입자 시장 규모와 동향 분석 - 분자별(2018-2030년)
siRNA
mRNA
기타

제6장 지질 나노입자 시장 : 용도 비즈니스 분석

부문 대시보드
지질 나노입자의 전체적인 변동 분석
세계의 지질 나노입자 시장 규모와 동향 분석 - 용도별(2018-2030년)
치료
연구

제7장 지질 나노입자 시장 : 적응증 비즈니스 분석

부문 대시보드
지질 나노입자의 전체적인 변동 분석
세계의 지질 나노입자 시장 규모와 동향 분석 - 적응증별(2018-2030년)
암
전염병
혈액 질환
기타

제8장 지질 나노입자 시장 : 최종 용도 비즈니스 분석

부문 대시보드
지질 나노입자의 전체적인 변동 분석
세계의 지질 나노입자 시장 규모와 동향 분석 - 최종 용도별(2018-2030년)
제약 및 생명공학 기업
학술 및 연구기관
기타

제9장 지질 나노입자 시장 : LNP, 분자, 용도, 적응증, 최종 용도에 따른 지역별, 추정 및 동향 분석

지역 대시보드
시장 규모와 예측과 동향 분석(2018-2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제10장 경쟁 구도

기업/경쟁의 분류
전략 매핑
기업 포지션 분석(2024년)
기업 프로파일/상장 기업
- Merck KGaA
- Evonik Industries AG
- Gattefosse
- FUJIFILM Pharmaceutical
- Danaher(Precision NanoSystems)
- Creative Biolabs
- IOI Oleo GmbH
- NOF Corporation
- Lipoid GmbH
- Cyman Chemical

KTH

영문 목차

영문목차

Lipid Nanoparticle Market Growth & Trends:

The global lipid nanoparticle market is anticipated to reach USD 1.54 billion by 2030 and is projected to grow at a CAGR of 13.64% during the forecast period, according to a new report by Grand View Research, Inc. The lipid market has experienced significant growth driven by increasing demand for advanced drug delivery systems, particularly in the fields of gene therapy, oncology, and vaccines. LNPs offer a highly efficient method for encapsulating and delivering a wide range of therapeutic molecules-including mRNA, siRNA, and small molecules-directly to target cells with improved stability and reduced degradation. The surge in R&D activities and growing investment in nanomedicine by both public institutions and private players have played a critical role in supporting the widespread adoption of LNP-based drug formulations across the pharmaceutical and biotechnology sectors.

The development of COVID-19 vaccines that utilized LNP-based delivery systems for mRNA vaccines garnered significant attention and resources during the pandemic. This increased focus on vaccine delivery technologies has indirectly benefited the market by driving innovation and investment in LNP formulation and manufacturing capabilities. Regulatory agencies expedited the review and approval processes for COVID-19 therapeutics and vaccines, including those utilizing LNP technology. While this facilitated rapid market entry for COVID-19 treatments, it also underscored the need for streamlined regulatory pathways and standards for LNP-based products in other therapeutic areas, potentially shaping future regulatory frameworks and market dynamics.

Moreover, strategic collaborations, technological advancements in lipid formulation, and increased awareness of precision medicine continue to drive market growth. Companies are now investing in next-generation LNP platforms designed for targeted delivery, lower toxicity, and enhanced payload versatility. Innovations such as ionizable lipids, hybrid lipid-polymer systems, and surface modifications are expanding the scope of LNPs in treating complex diseases, including rare genetic disorders. These developments, coupled with a favorable regulatory landscape and rising demand for personalized treatments, are expected to sustain strong momentum in the market over the coming years.

Lipid Nanoparticle Market Report Highlights:

Based on LNP, the liposomes segment dominated the overall market with the largest revenue share in 2024. Regulatory approvals of liposome-based drugs and their expanding use in cosmetic and nutraceutical applications continue to support market growth.
In terms of molecule, the mRNA segment dominated the overall market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR during the forecast period. As pharmaceutical companies and biotech firms increasingly invest in mRNA therapeutics, the demand for optimized LNP delivery systems continues to rise, fueling market growth.
Therapeutics dominated the application segment in 2024 owing to the increasing collaborations between research institutions and industry players for drug development and growing government funding,
In 2024, cancer dominated the disease indication segment and is expected to witness a significant CAGR over the forecast period. The rising cancer burden and the potential of LNPs in cancer treatment are driving significant research and development efforts in this area.
Pharmaceutical & biotechnology companies dominated the end use segment and the academic & research institute segment is expected to register the fastest CAGR during the forecast period.
North America dominated the market in 2024 owing to factors such as the significant burden of infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. LNP
- 1.2.2. Molecule
- 1.2.3. Application
- 1.2.4. Indication
- 1.2.5. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
  - 3.3.1.1. Growing Demand for Drug Delivery Systems
  - 3.3.1.2. Rise in Pharmaceutical Research and Development
  - 3.3.1.3. Increasing Focus on Nanotechnology
  - 3.3.1.4. Government Support and Funding for RNA-based therapies
- 3.3.2. Market Restraint Analysis
  - 3.3.2.1. High Development Costs
  - 3.3.2.2. Stringent Regulations Related to Approval and Commercialization
3.4. Industry Analysis Tools
- 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
- 3.4.2. Porter's Five Forces Analysis
- 3.4.3. COVID-19 Impact Analysis

Chapter 4. Lipid Nanoparticle Market: LNP Business Analysis

4.1. Segment Dashboard
4.2. Global Lipid Nanoparticle Movement Analysis
4.3. Global Lipid Nanoparticle Market Size & Trend Analysis, by LNP, 2018 to 2030 (USD Million)
4.4. Liposomes
- 4.4.1. Global Liposomes Market, 2018 - 2030 (USD Million)
4.5. Solid Lipid Nanoparticles
- 4.5.1. Global Solid Lipid Nanoparticles Market, 2018 - 2030 (USD Million)
4.6. Nanostructured Lipid Carriers
- 4.6.1. Global Nanostructured Lipid Carriers Market, 2018 - 2030 (USD Million)
4.7. Others
- 4.7.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 5. Lipid Nanoparticle Market: Molecule Business Analysis

5.1. Segment Dashboard
5.2. Global Lipid Nanoparticle Movement Analysis
5.3. Global Lipid Nanoparticle Market Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
5.4. siRNA
- 5.4.1. Global siRNA Market, 2018 - 2030 (USD Million)
5.5. mRNA
- 5.5.1. Global mRNA Market, 2018 - 2030 (USD Million)
5.6. Others
- 5.6.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 6. Lipid Nanoparticle Market: Application Business Analysis

6.1. Segment Dashboard
6.2. Global Lipid Nanoparticle Movement Analysis
6.3. Global Lipid Nanoparticle Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Therapeutics
- 6.4.1. Global Therapeutics Market, 2018 - 2030 (USD Million)
6.5. Research
- 6.5.1. Global Research Market, 2018 - 2030 (USD Million)

Chapter 7. Lipid Nanoparticle Market: Indication Business Analysis

7.1. Segment Dashboard
7.2. Global Lipid Nanoparticle Movement Analysis
7.3. Global Lipid Nanoparticle Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
7.4. Cancer
- 7.4.1. Global Cancer Market, 2018 - 2030 (USD Million)
7.5. Infectious Diseases
- 7.5.1. Global Infectious Diseases Market, 2018 - 2030 (USD Million)
7.6. Blood Diseases
- 7.6.1. Global Blood Diseases Market, 2018 - 2030 (USD Million)
7.7. Others
- 7.7.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 8. Lipid Nanoparticle Market: End Use Business Analysis

8.1. Segment Dashboard
8.2. Global Lipid Nanoparticle Movement Analysis
8.3. Global Lipid Nanoparticle Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
8.4. Pharmaceutical & Biotechnology Companies
- 8.4.1. Global Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
8.5. Academic & Research Institutes
- 8.5.1. Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
8.6. Others
- 8.6.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 9. Lipid Nanoparticle Market: Regional Estimates & Trend Analysis by LNP, Molecule, Application, Indication, & End Use

9.1. Regional Dashboard
9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
9.3. North America
- 9.3.1. North America Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.2. U.S.
  - 9.3.2.1. Key Country Dynamics
  - 9.3.2.2. Competitive Scenario
  - 9.3.2.3. Target Disease Prevalence
  - 9.3.2.4. Regulatory Framework
  - 9.3.2.5. U.S. Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.3. Canada
  - 9.3.3.1. Key Country Dynamics
  - 9.3.3.2. Competitive Scenario
  - 9.3.3.3. Target Disease Prevalence
  - 9.3.3.4. Regulatory Framework
  - 9.3.3.5. Canada Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.4. Mexico
  - 9.3.4.1. Key Country Dynamics
  - 9.3.4.2. Competitive Scenario
  - 9.3.4.3. Target Disease Prevalence
  - 9.3.4.4. Regulatory Framework
  - 9.3.4.5. Mexico Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Europe
- 9.4.1. Europe Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.2. UK
  - 9.4.2.1. Key Country Dynamics
  - 9.4.2.2. Competitive Scenario
  - 9.4.2.3. Target Disease Prevalence
  - 9.4.2.4. Regulatory Framework
  - 9.4.2.5. UK Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.3. Germany
  - 9.4.3.1. Key Country Dynamics
  - 9.4.3.2. Competitive Scenario
  - 9.4.3.3. Target Disease Prevalence
  - 9.4.3.4. Regulatory Framework
  - 9.4.3.5. Germany Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.4. France
  - 9.4.4.1. Key Country Dynamics
  - 9.4.4.2. Competitive Scenario
  - 9.4.4.3. Target Disease Prevalence
  - 9.4.4.4. Regulatory Framework
  - 9.4.4.5. France Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.5. Italy
  - 9.4.5.1. Key Country Dynamics
  - 9.4.5.2. Competitive Scenario
  - 9.4.5.3. Target Disease Prevalence
  - 9.4.5.4. Regulatory Framework
  - 9.4.5.5. Italy Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.6. Spain
  - 9.4.6.1. Key Country Dynamics
  - 9.4.6.2. Competitive Scenario
  - 9.4.6.3. Target Disease Prevalence
  - 9.4.6.4. Regulatory Framework
  - 9.4.6.5. Spain Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.7. Denmark
  - 9.4.7.1. Key Country Dynamics
  - 9.4.7.2. Competitive Scenario
  - 9.4.7.3. Target Disease Prevalence
  - 9.4.7.4. Regulatory Framework
  - 9.4.7.5. Denmark Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.8. Sweden
  - 9.4.8.1. Key Country Dynamics
  - 9.4.8.2. Competitive Scenario
  - 9.4.8.3. Target Disease Prevalence
  - 9.4.8.4. Regulatory Framework
  - 9.4.8.5. Sweden Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.9. Norway
  - 9.4.9.1. Key Country Dynamics
  - 9.4.9.2. Competitive Scenario
  - 9.4.9.3. Target Disease Prevalence
  - 9.4.9.4. Regulatory Framework
  - 9.4.9.5. Norway Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Asia Pacific
- 9.5.1. Asia Pacific Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.2. Japan
  - 9.5.2.1. Key Country Dynamics
  - 9.5.2.2. Competitive Scenario
  - 9.5.2.3. Target Disease Prevalence
  - 9.5.2.4. Regulatory Framework
  - 9.5.2.5. Japan Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.3. China
  - 9.5.3.1. Key Country Dynamics
  - 9.5.3.2. Competitive Scenario
  - 9.5.3.3. Target Disease Prevalence
  - 9.5.3.4. Regulatory Framework
  - 9.5.3.5. China Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.4. India
  - 9.5.4.1. Key Country Dynamics
  - 9.5.4.2. Competitive Scenario
  - 9.5.4.3. Target Disease Prevalence
  - 9.5.4.4. Regulatory Framework
  - 9.5.4.5. India Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.5. Australia
  - 9.5.5.1. Key Country Dynamics
  - 9.5.5.2. Competitive Scenario
  - 9.5.5.3. Target Disease Prevalence
  - 9.5.5.4. Regulatory Framework
  - 9.5.5.5. Australia Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.6. Thailand
  - 9.5.6.1. Key Country Dynamics
  - 9.5.6.2. Competitive Scenario
  - 9.5.6.3. Target Disease Prevalence
  - 9.5.6.4. Regulatory Framework
  - 9.5.6.5. Thailand Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.7. South Korea
  - 9.5.7.1. Key Country Dynamics
  - 9.5.7.2. Competitive Scenario
  - 9.5.7.3. Target Disease Prevalence
  - 9.5.7.4. Regulatory Framework
  - 9.5.7.5. South Korea Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Latin America
- 9.6.1. Latin America Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.6.2. Brazil
  - 9.6.2.1. Key Country Dynamics
  - 9.6.2.2. Competitive Scenario
  - 9.6.2.3. Target Disease Prevalence
  - 9.6.2.4. Regulatory Framework
  - 9.6.2.5. Brazil Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.6.3. Argentina
  - 9.6.3.1. Key Country Dynamics
  - 9.6.3.2. Competitive Scenario
  - 9.6.3.3. Target Disease Prevalence
  - 9.6.3.4. Regulatory Framework
  - 9.6.3.5. Argentina Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.7. MEA
- 9.7.1. MEA Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.2. South Africa
  - 9.7.2.1. Key Country Dynamics
  - 9.7.2.2. Competitive Scenario
  - 9.7.2.3. Target Disease Prevalence
  - 9.7.2.4. Regulatory Framework
  - 9.7.2.5. South Africa Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.3. Saudi Arabia
  - 9.7.3.1. Key Country Dynamics
  - 9.7.3.2. Competitive Scenario
  - 9.7.3.3. Target Disease Prevalence
  - 9.7.3.4. Regulatory Framework
  - 9.7.3.5. Saudi Arabia Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.4. UAE
  - 9.7.4.1. Key Country Dynamics
  - 9.7.4.2. Competitive Scenario
  - 9.7.4.3. Target Disease Prevalence
  - 9.7.4.4. Regulatory Framework
  - 9.7.4.5. UAE Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.5. Kuwait
  - 9.7.5.1. Key Country Dynamics
  - 9.7.5.2. Competitive Scenario
  - 9.7.5.3. Target Disease Prevalence
  - 9.7.5.4. Regulatory Framework
  - 9.7.5.5. Kuwait Lipid nanoparticle market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Position Analysis, 2024
10.4. Company Profiles/Listing
- 10.4.1. Merck KGaA
  - 10.4.1.1. Overview
  - 10.4.1.2. Financial Performance
  - 10.4.1.3. Product Benchmarking
  - 10.4.1.4. Strategic Initiatives
- 10.4.2. Evonik Industries AG
  - 10.4.2.1. Overview
  - 10.4.2.2. Financial Performance
  - 10.4.2.3. Product Benchmarking
  - 10.4.2.4. Strategic Initiatives
- 10.4.3. Gattefosse
  - 10.4.3.1. Overview
  - 10.4.3.2. Financial Performance
  - 10.4.3.3. Product Benchmarking
  - 10.4.3.4. Strategic Initiatives
- 10.4.4. FUJIFILM Pharmaceutical
  - 10.4.4.1. Overview
  - 10.4.4.2. Financial Performance
  - 10.4.4.3. Product Benchmarking
  - 10.4.4.4. Strategic Initiatives
- 10.4.5. Danaher (Precision NanoSystems)
  - 10.4.5.1. Overview
  - 10.4.5.2. Financial Performance
  - 10.4.5.3. Product Benchmarking
  - 10.4.5.4. Strategic Initiatives
- 10.4.6. Creative Biolabs
  - 10.4.6.1. Overview
  - 10.4.6.2. Financial Performance
  - 10.4.6.3. Product Benchmarking
  - 10.4.6.4. Strategic Initiatives
- 10.4.7. IOI Oleo GmbH
  - 10.4.7.1. Overview
  - 10.4.7.2. Financial Performance
  - 10.4.7.3. Product Benchmarking
  - 10.4.7.4. Strategic Initiatives
- 10.4.8. NOF Corporation
  - 10.4.8.1. Overview
  - 10.4.8.2. Financial Performance
  - 10.4.8.3. Product Benchmarking
  - 10.4.8.4. Strategic Initiatives
- 10.4.9. Lipoid GmbH
  - 10.4.9.1. Overview
  - 10.4.9.2. Financial Performance
  - 10.4.9.3. Product Benchmarking
  - 10.4.9.4. Strategic Initiatives
- 10.4.10. Cyman Chemical
  - 10.4.10.1. Overview
  - 10.4.10.2. Financial Performance
  - 10.4.10.3. Product Benchmarking
  - 10.4.10.4. Strategic Initiatives